Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis
Brain Research · 2024-01 · 1822 · 148648
DOI: 10.1016/j.brainres.2023.148648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2024-01. Verfasst von Emily A B Gilbert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Anatomy, Department of Surgery, University of Toronto, Toronto, ON M5S1A8, Canada; Donnelly Centre for Cellular and Biomolecular Research…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lungs for Life Foundation, Canada First Research Excellence Fund, Stem Cell Network.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation, death or damage of oligodendrocytes, and axonal degeneration. Current MS treatments are non-curative, associated with undesired side-effects, and expensive, highlighting the need for expanded therapeutic options for patients. There is great interest in developing interventions using drugs or therapeutics to reduce symptom onset and protect pre-existing myelin. Metformin is a well-tolerated drug used to treat Type 2 diabetes that has pleiotropic effects in the central nervous system (CNS), including reducing inflammation, enhancing oligodendrogenesis, increasing the survival/proliferation of neural stem cells (NSCs), and increasing myelination. Here, we investigated whether metformin administration could improve functional outcomes, modulate oligodendrocyte precursor cells (OPCs), and reduce inflammation in a well-established mouse model of MS- experimental autoimmune encephalomyelitis (EAE). Male and female mice received metformin treatment at the time of EAE induction ("acute") or upon presentation of disease symptoms ("delayed"). We found that acute metformin treatment improved functional outcomes, concomitant with reduced microglia numbers and decreased dysmyelination. Conversely, delayed metformin treatment did not improve functional outcomes. Our findings reveal that metformin administration can improve EAE outcomes when administered before symptom onset in both sexes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Anatomy, Department of Surgery, University of Toronto, Toronto, ON M5S1A8, Canada; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S3E1, Canada.
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S3E1, Canada.
- Division of Anatomy, Department of Surgery, University of Toronto, Toronto, ON M5S1A8, Canada; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S3E1, Canada; Institute of Biom…
Förderung
- Lungs for Life Foundation
- Canada First Research Excellence Fund
- Stem Cell Network
- University of Toronto
- Ontario Institute for Regenerative Medicine
Zitieren
APA
Gilbert, E. A. B., Livingston, J., Flores, E. G., Khan, M., Kandavel, H., & Morshead, C. M. (2024). Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis. Brain Research, 1822, 148648. https://doi.org/10.1016/j.brainres.2023.148648
Vancouver
Gilbert EAB, Livingston J, Flores EG, Khan M, Kandavel H, Morshead CM. Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis. Brain Research. 2024;1822:148648. doi:10.1016/j.brainres.2023.148648
BibTeX
@article{Gilbert2024,
author = {Gilbert, Emily A B and Livingston, Jessica and Flores, Emilio Garcia and Khan, Monoleena and Kandavel, Harini and Morshead, Cindi M},
title = {Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis},
journal = {Brain Research},
year = {2024},
volume = {1822},
pages = {148648},
doi = {10.1016/j.brainres.2023.148648}
}
EUVIMED